Results 101 to 110 of about 49,828 (259)

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report

Medicine Science, 2018
Vildagliptin is a new generation theurapeutic agent of diabetes mellitus which belongs to dipeptidyl peptidase-IV inhibitor class acting via the incretin hormone system.
Serhat Sayin, Ethem Omeroglu, Semra Aslan Bilgin   +2 more
doaj   +1 more source

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes

, 2008
Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian LerchCochrane Metabolic and Endocrine Disorders Group, Department of General Practice, Heinrich-Heine University Duesseldorf, Duesseldorf, GermanyBackground: In type 2 diabetes ...
Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian Lerch, Bernd Richter   +3 more
core  

Characteristics of new users of dipeptidyl peptidase-4 inhibitors and biguanides.

, 2018
Characteristics of new users of dipeptidyl peptidase-4 inhibitors and biguanides.
Ian C. K. Wong (306894), Kenneth K. C. Man (6078836), Paul Stang (3414047), Yea-Huei Kao Yang (528537), Yukari Kamijima (5721233), Kiyoshi Kubota (561420), Patrick Ryan (532054), Chien-Chou Su (6078839), Soko Setoguchi (427043), Shinya Kimura (247648), Edward Chia-Cheng Lai (528535), Martijn Schuemie (505609), Yinghong Zhang (6078842)   +12 more
core   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, EarlyView.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins

Acta Pharmaceutica Sinica B, 2014
Dipeptidyl peptidase 4 (DPP4) is recognised as an attractive anti-diabetic drug target, and several DPP4 inhibitors are already on the market. As members of the same gene family, dipeptidyl peptidase 8 (DPP8) and dipeptidyl peptidase 9 (DPP9) share high ...
Jinglong Liu, Yi Huan, Caina Li, Minzhi Liu, Zhufang Shen   +4 more
doaj   +1 more source

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand

, 2016
Unchalee Permsuwan,1 Piyameth Dilokthornsakul,2 Surasak Saokaew,2–4 Kednapa Thavorn,5–7 Nathorn Chaiyakunapruk2,4,8,9 1Faculty of Pharmacy Chiang Mai University, Chiang Mai, 2Center of Pharmaceutical Outcomes Research, Faculty of ...
Chaiyakunapruk N, Thavorn K, Dilokthornsakul P, Permsuwan U, Saokaew S   +4 more
core  

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Vildagliptin: the first innovative DDP-4 inhibitor

Сахарный диабет, 2010
A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity
Edvin Villkhauer
doaj   +1 more source

Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes

, 2009
Galina Smushkin, Adrian VellaDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, MN, USAAbstract: Postprandial hyperglycemia in type 2 diabetes is characterized by impaired insulin secretion and ...
Galina Smushkin, Adrian Vella
core  

Lactobacilli possess inhibitory activity against dipeptidyl peptidase-4 (DPP-4)

, 2015
Dipeptidyl peptidase 4 (DPP-4) enzymatically inactivates incretin hormones, and DPP-4 inhibitor drugs are clinically approved therapies for type 2 diabetes.
Panwar, Harsh, Calderwood, Danielle, Green, Brian D., Grover, Sunita, Grant, Irene R.; id_orcid   +4 more
core   +1 more source